Eli Lilly and Company
LLY
$1136.11
-0.19%
Eli Lilly and Company is a global pharmaceutical firm focused on neuroscience, cardiometabolic health, oncology, and immunology, with flagship products including Mounjaro, Zepbound, Verzenio, Jardiance, Trulicity, Taltz, and Olumiant. As the world's most valuable healthcare company by market capitalization, Lilly has become the defining platform in the GLP-1 incretin era, leveraging its tirzepatide franchise to outpace Novo Nordisk in the obesity and diabetes duopoly while aggressively diversifying into new therapeutic areas. The current investor narrative centers on three pillars: the durability and expansion of the cardiometabolic franchise (reinforced by the August 2026 FDA approval of Mounjaro for cardiovascular risk reduction in diabetes), a strategic pivot into immunology via the $2.9 billion acquisition of Merida Biosciences, and the tension between Lilly's premium valuation and intensifying competition from Novo Nordisk, Amgen's MariTide, and emerging oral GLP-1 entrants. The debate has shifted from pure growth enthusiasm to questions of whether Lilly can sustain its extraordinary revenue trajectory while absorbing heavy capital expenditure and R&D investment, with the stock's recent pullback reflecting these valuation and competitive anxieties.…
LLY
Eli Lilly and Company
$1136.11
Related headlines
Investment Opinion: Should I buy LLY Today?
The synthesized recommendation is Buy, anchored by the analyst consensus rating of 'buy' (mean 1.7) and an average target price of $1,318.66, implying 18.2% upside. The core thesis is that Lilly's hypergrowth revenue trajectory (55.55% YoY in Q1 2026) and expanding margins (net margin 37.36%) justify a premium valuation, and the recent pullback offers an attractive entry point for long-term investors.
Supporting evidence includes: 1) Revenue growth of 55.55% YoY, far exceeding large-cap pharma peers; 2) Net margin expansion to 37.36% from 21.68% a year ago, demonstrating operating leverage; 3) Forward PE of 23.62x, which is reasonable for a company expected to grow EPS to $66.16; 4) PEG ratio of 0.49, suggesting undervaluation relative to growth; and 5) Strong free cash flow of $13.58 billion TTM, funding dividends and buybacks. The stock's 47.52% one-year return also outperformed SPY by 31.30%.
The biggest risks that could invalidate the thesis are: 1) Competitive share loss to Novo Nordisk or Amgen, which could slow revenue growth below 30%; 2) Valuation compression if interest rates remain high or growth disappoints; and 3) Execution risk in the immunology pivot and manufacturing expansion. The rating would upgrade to Strong Buy if the stock pulls back to $1,000 (forward PE ~15x) while growth remains above 40%, or downgrade to Hold if revenue growth decelerates below 25% or if GLP-1 market share declines for two consecutive quarters. Relative to its history and peers, LLY appears fairly valued on forward earnings but overvalued on trailing metrics; the premium is justified only if growth persists.
Sign up to view all
LLY 12-Month Price Forecast
Lilly remains a compelling growth story, but the risk/reward is more balanced after the recent pullback. The company's hypergrowth revenue trajectory and margin expansion are undeniable, and the forward valuation is not unreasonable if consensus estimates are met. However, competitive threats from Novo Nordisk and Amgen are real, and the stock's premium multiple leaves little room for error. I would upgrade to high confidence if GLP-1 market share data shows sustained dominance and the immunology pipeline delivers positive readouts. Conversely, a downgrade to neutral would occur if revenue growth decelerates below 30% or if competitive losses become evident.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Eli Lilly and Company's 12-month outlook, with a consensus price target around $1324.87 and implied upside of +16.6% versus the current price.
Average Target
$1324.87
0 analysts
Implied Upside
+16.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$930 - $1600
Analyst target range
Lilly is covered by 29 analysts with a consensus recommendation of "buy" (recommendation mean of 1.7 on a 1-5 scale where 1 is strong buy), reflecting broad institutional bullishness. The average price target is $1,318.66, which implies approximately 18.2% upside from the current price of $1,115.70, while the consensus revenue estimate of $132.39 billion and EPS estimate of $66.16 for the forward period underscore expectations for continued hypergrowth. The consensus leans clearly bullish, with the recommendation mean of 1.7 indicating that the vast majority of covering analysts rate the stock a Buy or equivalent — a notable signal given the stock's recent 8.57% one-month decline, suggesting analysts view the pullback as a buying opportunity rather than the start of a sustained downtrend. The target price range spans from a low of $930.00 to a high of $1,600.00, representing a spread of $670 (72% of the current price), which signals meaningful disagreement about the company's trajectory. The high target of $1,600 implies roughly 43.4% upside and would require either significant multiple expansion, faster-than-expected GLP-1 adoption, successful pipeline readouts, or the immunology pivot (Merida Biosciences) delivering substantial returns; the low target of $930 implies approximately 16.6% downside and likely prices in competitive share loss to Novo Nordisk or Amgen, pricing pressure on GLP-1 drugs, or margin compression from manufacturing buildout. Institutional ratings from July 2026 show a uniformly bullish pattern — Citigroup, Bernstein, UBS, Guggenheim, B of A, Truist, Morgan Stanley, RBC, JP Morgan, and Cantor Fitzgerald all maintained Buy/Outperform/Overweight ratings with no downgrades — indicating that despite the recent price weakness, sell-side conviction remains strong. The relatively wide target spread, combined with the recent underperformance, suggests the market is in a period of price discovery where the bull case (GLP-1 dominance and pipeline diversification) and bear case (valuation, competition, and execution risk) are actively competing for dominance.
Drowning in data?
Find the real signal!
Bulls vs Bears: LLY Investment Factors
The bull case currently has stronger evidence, driven by exceptional revenue growth (55.55% YoY), expanding margins (net margin 37.36%), and a robust analyst consensus with 18.2% upside to the average target. However, the bear case is gaining traction due to the stock's recent underperformance (-8.57% in one month), premium valuation (trailing PE 46.73x), and intensifying competition from Novo Nordisk and Amgen. The single most important tension is whether Lilly can sustain its hypergrowth trajectory long enough to justify its premium multiple, or whether competitive pressures and valuation gravity will force a re-rating. Resolution hinges on upcoming GLP-1 market share data and the success of pipeline diversification efforts.
Bullish
- Hypergrowth revenue acceleration: Q1 2026 revenue reached $19.799 billion, up 55.55% year-over-year from $12.729 billion in Q1 2025, marking the fifth consecutive quarter of accelerating growth. This trajectory is exceptionally rare at Lilly's scale and underscores the dominant demand for its tirzepatide franchise.
- Massive margin expansion: Net margin expanded to 37.36% in Q1 2026 from 21.68% a year earlier, while operating margin hit 44.70% and gross margin remained stable at 81.93%. This demonstrates powerful operating leverage as revenue growth outpaces expense growth.
- Attractive PEG and forward PE: The PEG ratio of 0.49 suggests undervaluation relative to growth, and the forward PE of 23.62x represents a 49.5% compression from the trailing PE of 46.73x. If consensus EPS of $66.16 is achieved, the stock is priced at a reasonable multiple for a hypergrowth pharma leader.
- Strong analyst consensus and upside: 29 analysts rate LLY a 'buy' with a mean recommendation of 1.7, and the average price target of $1,318.66 implies 18.2% upside from the current $1,115.70. The high target of $1,600 suggests 43.4% upside, reflecting confidence in the GLP-1 franchise and pipeline.
Bearish
- Premium valuation versus peers: Trailing PE of 46.73x, PS of 14.81x, and EV/EBITDA of 35.81x are well above large-cap pharma norms (typically 15-20x PE, 3-5x PS, 10-15x EBITDA). This premium leaves little room for execution missteps.
- Revenue concentration risk: Cardiometabolic health accounts for $15.76 billion, or 79.6% of total revenue, making Lilly heavily dependent on the GLP-1/incretin franchise. Any competitive or regulatory setback in this segment would disproportionately impact the entire company.
- Recent momentum deterioration: The stock is down 8.57% over the past month and 1.53% over three months, underperforming SPY by 7.51% and 4.57% respectively. YTD gain of 3.27% lags SPY's 12.08%, signaling a consolidation phase and potential trend reversal.
- Intensifying competition: Novo Nordisk's semaglutide met goals in a pediatric obesity study, Amgen's MariTide offers once-monthly dosing convenience, and oral GLP-1 entrants are emerging. These threats could erode Lilly's market share and pricing power.
LLY Technical Analysis
LLY is in a sustained longer-term uptrend that has recently entered a corrective phase, with the stock up 47.52% over the past year but trading at $1,115.70, which represents approximately 69.6% of its 52-week range (52-week low of $712.05, 52-week high of $1,292.65). The stock sits about 13.7% below its 52-week high and 56.7% above its 52-week low, positioning it in the upper-middle portion of its annual range — a zone that historically reflects a healthy uptrend experiencing a normal pullback rather than a broken trend or a deep-value opportunity. The 1-year gain of 47.52% versus SPY's 16.22% (relative strength of +31.30%) confirms significant long-term outperformance, though the current positioning suggests momentum has cooled from its peak. Recent momentum has deteriorated sharply: the stock is down 8.57% over the past month and 1.53% over three months, contrasting starkly with the +47.52% one-year gain and +13.26% six-month gain. This divergence — where the 1-month and 3-month trends are negative while the 1-year trend remains strongly positive — signals a meaningful mean-reversion or consolidation phase, with the stock underperforming SPY by 7.51% over the past month (relative strength of -7.51%) and by 4.57% over three months. The YTD gain of just 3.27% versus SPY's 12.08% (relative strength of -8.81%) further underscores that 2026 has been a year of underperformance and digestion following the prior year's explosive move. Key technical levels are well-defined: support rests at the 52-week low of $712.05, with intermediate support likely around the $1,100 psychological level and the recent consolidation zone near $1,115-$1,150; resistance sits at the 52-week high of $1,292.65, with the $1,230-$1,280 area representing the recent swing-high cluster from August 2026. A breakout above $1,292.65 would signal renewed momentum and likely re-establish the uptrend, while a breakdown below $1,100 could open the door to a deeper correction toward the $1,000 level. The stock's beta of 0.502 is notably low — roughly half the market's volatility — which is unusual for a high-growth pharmaceutical name and suggests that despite its premium valuation, LLY has exhibited defensive characteristics relative to SPY, though the max drawdown of -23.31% indicates that idiosyncratic risk remains substantial.
Beta
0.50
0.50x market volatility
Max Drawdown
-23.3%
Largest decline past year
52-Week Range
$712-$1293
Price range past year
Annual Return
+51.8%
Cumulative gain past year
| Period | LLY Return | S&P 500 |
|---|---|---|
| 1m | -3.7% | -2.4% |
| 3m | +2.2% | +2.2% |
| 6m | +23.8% | +14.8% |
| 1y | +51.8% | +14.6% |
| ytd | +5.2% | +11.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
LLY Fundamental Analysis
Lilly's revenue trajectory is exceptionally strong and accelerating: Q1 2026 revenue reached $19.799 billion, representing 55.55% year-over-year growth versus Q1 2025's $12.729 billion, continuing a multi-quarter acceleration pattern from $15.558 billion in Q2 2025 (+37.7% YoY), $17.601 billion in Q3 2025, and $19.292 billion in Q4 2025. The cardiometabolic health segment dominates the business at $15.76 billion (approximately 79.6% of total revenue), followed by oncology at $2.268 billion, immunology at $1.203 billion, and neuroscience at $382 million — meaning the company's fortunes remain heavily concentrated in the GLP-1/incretin franchise, which is both its greatest strength and its key concentration risk. The sequential revenue progression from $12.7B to $19.8B over five quarters demonstrates not just growth but accelerating growth, which is rare at this scale and explains why the market has historically awarded such a premium multiple. Profitability is robust and expanding: Q1 2026 net income was $7.396 billion with a net margin of 37.36%, up from $2.759 billion and a 21.68% net margin in Q1 2025, while gross margin stands at 81.93% and operating margin at 44.70%. The net income ratio has expanded dramatically from 21.68% (Q1 2025) to 37.36% (Q1 2026), driven by operating leverage as revenue growth outpaces expense growth — R&D rose to $3.51 billion in Q1 2026 from $2.734 billion a year earlier, but as a percentage of revenue it declined from 21.5% to 17.7%. Gross margin has been remarkably stable in the 81-85% range across all recent quarters, reflecting strong pricing power and manufacturing efficiency despite heavy capacity expansion. The balance sheet shows a debt-to-equity ratio of 1.60 and a current ratio of 1.58, indicating adequate but not fortress-like liquidity, with total debt to capitalization at 58.16%. Free cash flow on a TTM basis is $13.58 billion, though quarterly FCF has been volatile — ranging from -$1.60 billion in Q1 2025 to $8.61 billion in Q3 2025 and $3.01 billion in Q1 2026 — reflecting massive capital expenditure ($2.33 billion in Q1 2026 alone) to build manufacturing capacity for GLP-1 production. ROE is an extraordinary 77.78% and ROA is 20.36%, both exceptionally high for the pharmaceutical industry, though the ROE is amplified by the company's equity multiplier of approximately 3.74x. The company generates sufficient operating cash flow ($5.33 billion in Q1 2026) to fund its dividend ($1.55 billion paid) and buybacks ($2.36 billion), but the heavy capex program means external financing capacity remains important.
Quarterly Revenue
$19.8B
2026-03
Revenue YoY Growth
+55.5%
YoY Comparison
Gross Margin
81.9%
Latest Quarter
Free Cash Flow
$13.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is LLY Overvalued?
Because Lilly is solidly profitable with trailing net income of approximately $22.2 billion (sum of last four quarters) and positive EBITDA of $9.69 billion in the most recent quarter, the PE ratio is the appropriate primary valuation metric. The trailing PE stands at 46.73x while the forward PE is 23.62x — a dramatic 49.5% compression that implies the market expects earnings to roughly double over the next twelve months, consistent with the consensus EPS estimate of $66.16 versus the trailing EPS of approximately $23.88. This wide trailing-to-forward gap reflects the market's confidence in Lilly's earnings acceleration as GLP-1 volumes scale and operating leverage kicks in, though it also means the stock is priced for near-flawless execution. On a peer comparison basis, Lilly's trailing PE of 46.73x represents a substantial premium to the drug manufacturers-general industry average, which typically ranges from 15-20x for large-cap pharma; even accounting for Lilly's superior growth, the premium is significant. The PS ratio of 14.81x and EV/EBITDA of 35.81x are also well above sector norms (large pharma typically trades at 3-5x sales and 10-15x EBITDA), while the PB ratio of 36.37x is extreme by any historical standard. However, the PEG ratio of 0.49 suggests that when adjusted for growth, Lilly may actually be undervalued relative to its earnings expansion rate — a nuance that bulls emphasize. Historically, Lilly's PE has ranged from a low of around 27.8x (Q1 2026) to a high of over 200x (Q3 2024, distorted by a temporary earnings trough), with the current 46.73x sitting in the middle-to-upper portion of its recent range. The PS ratio of 14.81x is notably below its historical peak of 78.14x (Q1 2024) and the 50.02x recorded in Q4 2025, suggesting significant multiple compression has already occurred even as the stock price has risen — a function of revenue growth outpacing price appreciation. The forward PE of 23.62x, if achieved, would represent the lowest valuation multiple in Lilly's recent history, implying that either the stock is attractively valued on forward earnings or that the market is skeptical of the consensus EPS estimates.
PE
46.6x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 28x~76x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
31.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are significant given Lilly's premium valuation and capital intensity. The debt-to-equity ratio of 1.60 and total debt-to-capitalization of 58.16% indicate meaningful leverage, while free cash flow has been volatile, ranging from -$1.60 billion in Q1 2025 to $8.61 billion in Q3 2025 and $3.01 billion in Q1 2026. The company's heavy capex program ($2.33 billion in Q1 2026 alone) to expand GLP-1 manufacturing capacity consumes cash and could pressure liquidity if revenue growth decelerates. Additionally, revenue concentration is extreme: cardiometabolic health represents 79.6% of total revenue, so any setback in the tirzepatide franchise would have an outsized impact on financial performance.
Market and competitive risks are intensifying. The stock's beta of 0.502 suggests lower volatility relative to the market, but its max drawdown of -23.31% indicates idiosyncratic risk remains substantial. Valuation compression is a real threat: trailing PE of 46.73x and PS of 14.81x are well above large-cap pharma averages, leaving little margin for error. Recent news highlights competitive threats: Novo Nordisk's semaglutide met goals in a pediatric obesity study, Amgen's MariTide offers once-monthly dosing convenience, and oral GLP-1 entrants are emerging. These developments could erode Lilly's market share and pricing power, especially if payers push for lower-cost alternatives.
In a worst-case scenario, a combination of competitive share loss, pricing pressure, and pipeline disappointments could trigger a severe re-rating. The 52-week low of $712.05 represents a 36.2% decline from the current price of $1,115.70, and the analyst low target of $930 implies 16.6% downside. If GLP-1 competition intensifies and Lilly's growth decelerates below 20%, the stock could fall toward $800-$900, a loss of 19-28%. A more extreme scenario, such as regulatory setbacks or manufacturing failures, could push the stock to the 52-week low, resulting in a 36% loss. Investors should be prepared for significant drawdowns given the stock's high valuation and concentrated revenue base.
FAQ
The most severe risk is competitive pressure: Novo Nordisk's semaglutide and Amgen's MariTide could erode Lilly's GLP-1 market share, potentially slowing revenue growth below 30%. Financial risks include high leverage (debt-to-equity 1.60) and volatile free cash flow due to heavy capex ($2.33 billion in Q1 2026). Valuation risk is significant, as the trailing PE of 46.73x leaves little room for error. Company-specific risks include revenue concentration (79.6% from cardiometabolic) and execution risk on the immunology pivot. Macro risks are moderate given the low beta of 0.502, but high interest rates could compress growth stock multiples.
The 12-month forecast is based on three scenarios: bull case (30% probability) targets $1,450-$1,600, assuming revenue growth exceeds 40% and pipeline success; base case (50% probability) targets $1,250-$1,350, assuming 30-35% revenue growth and stable margins; bear case (20% probability) targets $800-$930, assuming competitive share loss and growth deceleration below 20%. The base case is most likely, hinging on Lilly maintaining its GLP-1 dominance and delivering on consensus EPS of $66.16. The average analyst target of $1,318.66 aligns with the base case, implying 18.2% upside.
LLY appears overvalued on trailing metrics but fairly valued on forward earnings. The trailing PE of 46.73x and PS of 14.81x are well above large-cap pharma averages (15-20x PE, 3-5x PS), reflecting a significant premium. However, the forward PE of 23.62x represents a 49.5% compression, implying the market expects earnings to double. The PEG ratio of 0.49 suggests the stock is undervalued when adjusted for growth. Compared to its own history, the PS ratio of 14.81x is below its peak of 78.14x, indicating multiple compression has already occurred. The market is pricing in near-flawless execution, so any growth disappointment could trigger a re-rating.
From a risk/reward perspective, LLY offers an attractive opportunity for growth-oriented investors, with 18.2% upside to the average analyst target of $1,318.66 and a consensus buy rating. The stock's forward PE of 23.62x is reasonable given expected EPS growth to $66.16, and the PEG ratio of 0.49 suggests undervaluation relative to growth. However, the biggest downside risk is competitive share loss, which could push the stock toward the analyst low target of $930 (16.6% downside). It is a good buy for long-term investors who believe in the GLP-1 franchise's durability, but short-term traders should be cautious given the recent 8.57% monthly decline and technical weakness.
LLY is best suited for long-term investment, given its growth stage, low beta of 0.502, and modest dividend yield of 0.56%. The company's earnings visibility is strong, with consensus EPS of $66.16 for the forward period, but the stock's high valuation and competitive dynamics introduce volatility that makes short-term trading risky. A minimum holding period of 2-3 years is recommended to ride out potential drawdowns (max drawdown -23.31%) and benefit from the GLP-1 franchise's long-term growth. Short-term traders could exploit technical levels, but the risk/reward favors patient investors.
